The Institute for Bioanalytics's (IBA) assay development laboratory is offering customers enhanced assay development services with the recent acquisition of a Dotlab system.
The Dotlab system from Axela is an enabling platform for the development and deployment of assays.
Dotlab system customers in the pharmaceutical, biotech and diagnostic industries can now augment internal biomarker programmes with IBA's contract assay development expertise for single or multiplexed immunoassay development.
In addition to custom assay development, IBA is partnering with Axela to expand the menu of biomarker assays optimised for use with the Dotlab platform and the soon-to-be available Panelplus sensors.
Axela's new real-time sensor technology offers customers freedom to combine preconfigured assays with their novel markers to accelerate biomarker validation.
The Dotlab system's novel technology for performing immunoassays and real-time study of protein interactions has demonstrated enhanced performance in many application areas including cardiology, oncology, and infectious disease.
Benefits include extended dynamic range, simultaneous measurement of high and low abundance markers and concurrent detection of secondary information such as binding partners, isotype and avidity.
